This site is intended for healthcare professionals only
LoginRegister
No Promotional Campaigns for GLP-1 Obesity Drugs: CDSCO Cautions Pharma FirmsTelangana Drug Authority Reports 42,420 Inspections, 186 NSQ Drugs Between 2024-2025, Minister...
Takeda announces closing of partnership with Innovent Biologics for oncology medicinesTakeda eyes India for global clincal trials amid booming clinical trials market
Four new drugs for rare diseases on anvilFour new drugs for rare diseases on anvil, 5 medications for 7 ailments in mkt: VK Paul
Pill form of Wegovy gets USFDA approval for weight lossNovo Nordisk's Wegovy, Fiasp, Ryzodeg Injectables Stolen During Transit, DCGI Issues Alert
Misclassifying Drugs as NutraceuticalsFour senior employees of Medley Pharma booked over Palghar gas leak
Kotapally raid: Large cache of medicines bound for Maharashtra confiscatedKotapally raid: Large cache of medicines bound for Maharashtra confiscated
Ravenbhel Bilastine, Montelukast FDC Under Review, CDSCO Panel Seeks Pediatric Expert OpinionRavenbhel's Bilastine, Montelukast FDC Under Review, CDSCO Panel Seeks Pediatric Expert Opinion
From Breakthrough to Backlash: Novo Nordisks Ozempic Faces USD 2 Billion LawsuitFrom Breakthrough to Backlash: Novo Nordisk's Ozempic Faces USD 2 Billion Lawsuit
Aurobindo Pharma Slapped Rs 170 Crore GST DemandAurobindo Pharma Clarifies Zentiva Acquisition Reports 'Premature', No Binding Pact Finalised
CDSCO Digitisation Cuts Post-Approval Change Timelines in CGTs from 218 to 98 Days: DCGICDSCO Digitisation Cuts Post-Approval Change Timelines in CGTs from 218 to 98 Days: DCGI
PLI scheme brings down cost of rare disease treatment from crores to lakhsPLI scheme brings down cost of rare disease treatment from crores to lakhs
Aurobindo Arm CuraTeQ Partners STADA Arzneimittel AG to Commercialise Biosimilars in EuropeAurobindo Pharma in lead to acquire Zentiva for US 5.5 billion: ET Report
X